Cannabis Industry Sees a Boost as Rescheduling Takes Effect
The recent rescheduling of cannabis from a Schedule I to a Schedule III controlled substance has brought significant benefits to multi-state operators in the industry. Two of the largest pot retailers, Trulieve and Curaleaf, have already seen a surge in profits, with their shares increasing by over 50% in the past three months.
The rescheduling, which took effect on April 22, marks a major shift for the industry. The U.S. Department of Justice and the U.S. Drug Enforcement Administration have announced that medical marijuana will no longer be subject to the 280E provision of the Internal Revenue Code, which prohibited cannabis companies from deducting certain business expenses. This change is expected to have a positive impact on the industry, allowing companies to operate more efficiently and potentially increase their profitability.
Trulieve and Curaleaf, two of the largest cannabis companies in the United States, have already seen the benefits of the rescheduling. Both companies reported a profit in the first quarter, with their shares rising significantly over the past three months. The companies’ success is a sign that the rescheduling is having a positive impact on the industry, and investors are taking notice.
The rescheduling is not the only positive development for the cannabis industry. Hearings are scheduled to begin in June to determine whether all cannabis, including recreational cannabis, should be moved to Schedule III. This could lead to even more significant changes for the industry, potentially opening up new opportunities for growth and expansion.
Overall, the rescheduling of cannabis is a significant development for the industry, and it’s likely to have a positive impact on companies like Trulieve and Curaleaf. As the industry continues to evolve, investors may want to consider these companies as potential investment opportunities.
